Febuxostat inhibition of endothelial-bound XO: implications for targeting vascular ROS production. - Wikidata - wikimedia - TriplyDB

Febuxostat inhibition of endothelial-bound XO: implications for targeting vascular ROS production.

Febuxostat inhibition of endothelial-bound XO: implications for targeting vascular ROS production.

http://www.wikidata.org/entity/Q42127578

about

Interplay between oxidant species and energy metabolism Hypoxia and reoxygenation induce endothelial nitric oxide synthase uncoupling in endothelial cells through tetrahydrobiopterin depletion and S-glutathionylation.Inhibition of xanthine oxidase by the aldehyde oxidase inhibitor raloxifene: implications for identifying molybdopterin nitrite reductases Nox2-dependent glutathionylation of endothelial NOS leads to uncoupled superoxide production and endothelial barrier dysfunction in acute lung injury.Febuxostat, an inhibitor of xanthine oxidase, suppresses lipopolysaccharide-induced MCP-1 production via MAPK phosphatase-1-mediated inactivation of JNK Xanthine Oxidoreductase Function Contributes to Normal Wound Healing Reperfusion injury and reactive oxygen species: The evolution of a concept.Activation of the aryl hydrocarbon receptor sensitizes mice to nonalcoholic steatohepatitis by deactivating mitochondrial sirtuin deacetylase Sirt3.Xanthine oxidoreductase-catalyzed reduction of nitrite to nitric oxide: insights regarding where, when and how.Rationale and design of a multicenter randomized study for evaluating vascular function under uric acid control using the xanthine oxidase inhibitor, febuxostat: the PRIZE study.Xanthine oxidoreductase-catalyzed reactive species generation: A process in critical need of reevaluation.Fatty acid nitroalkenes ameliorate glucose intolerance and pulmonary hypertension in high-fat diet-induced obesity.An evidence-based review on urate-lowering treatments: implications for optimal treatment of chronic hyperuricemia.Xanthine oxidase inhibition by febuxostat attenuates experimental atherosclerosis in mice.Molecular biology of atherosclerosis.Dispelling dogma and misconceptions regarding the most pharmacologically targetable source of reactive species in inflammatory disease, xanthine oxidoreductase.Direct antioxidant properties of methotrexate: Inhibition of malondialdehyde-acetaldehyde-protein adduct formation and superoxide scavenging Uric Acid Amplifies Aβ Amyloid Effects Involved in the Cognitive Dysfunction/Dementia: Evidences From an Experimental Model In Vitro.An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Toward an Understanding of Structural Insights of Xanthine and Aldehyde Oxidases: An Overview of their Inhibitors and Role in Various Diseases.Effect of Febuxostat, a Xanthine Oxidase Inhibitor, on Cardiovascular Risk in Hyperuricemic Patients with Hypertension: A Prospective, Open-label, Pilot Study.XOR inhibition with febuxostat accelerates pulmonary endothelial barrier recovery and improves survival in lipopolysaccharide-induced murine sepsis.Febuxostat improves outcome in a rat model of cancer cachexia.Effects of xanthine oxidase inhibition with febuxostat on the development of nephropathy in experimental type 2 diabetes.Febuxostat, a novel xanthine oxidoreductase inhibitor, improves hypertension and endothelial dysfunction in spontaneously hypertensive rats.Febuxostat for hyperuricemia in patients with advanced chronic kidney disease Preservation of renal function during gout treatment with febuxostat: a quantitative study.As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout.The problem of cardio-renal diseases in patients with gout.The management of hyperuricemia: back to the pathophysiology of uric acid.Effective uric acid-lowering treatment for hypertensive patients with hyperuricemia.Serum and aqueous xanthine oxidase levels, and mRNA expression in anterior lens epithelial cells in pseudoexfoliation.Febuxostat for treating allopurinol-resistant hyperuricemia in patients with chronic kidney disease.

P2860

Q28383905-C6822EFE-F7FB-43BF-AE79-0B24D41CB1FB Q33739113-1BBE4A64-994A-486B-8045-E07AE21C5379 Q34663374-D7B9B843-9BD4-4E0F-822B-4AAE5220DFFC Q34726830-0CAF79EA-D23E-430F-A517-95F48B007BF2 Q35005708-3361B66F-59BF-4C62-8F3C-2A45D72CA643 Q35855645-FAB07358-695E-49FE-A66E-1144A89DEAB2 Q36221276-81267CFA-63B5-46E4-95F1-8301DCD5F9BC Q36826832-6293940C-A74E-447A-94A3-EB4EE1639DA2 Q36997192-E3DCF574-D6E8-41F2-83E9-98D7EB793A80 Q37018125-A88ED77A-77FA-4E2A-86CA-4059E6371D54 Q37133541-30A95E79-2168-4D0C-A6E7-8344EFBEA1E5 Q37591231-69EF3894-1C14-4CAB-9644-7B9874466BBD Q37641297-4589C750-93C1-4FBD-9382-8380F10A43F6 Q37676966-4BE2F12A-B3E4-4E74-ACB1-6DCA1EC81137 Q38125279-D6533F4B-B05D-4F1F-9808-8B21CF3AFD01 Q38494677-839EB382-0FA4-40B8-9542-DC5B6D8AE008 Q38695031-215A78D7-650A-469E-8897-FC269FF89AAA Q38754696-FE2A600D-428C-49E7-8557-CF2B1AB5DE48 Q39007529-ABBAAB5A-9423-42E9-9470-2D4239167C55 Q39411224-EBE93E19-5914-4698-ABF9-4A05AD971198 Q41202631-D6BDBD12-1671-43AB-9EA3-5305E3B9CD26 Q41386068-8234E0A0-8820-45A0-8D8B-7EFDC9BA35B5 Q41769219-7FC19D6B-2471-4C88-9159-D2DA535EAEBC Q41974155-437EDAA8-8471-4BE5-AEE8-185B22D05000 Q42152252-2D23A7AB-CB3B-4E03-92F6-83412A6F8ADE Q42268534-D6644459-8248-4F8B-AD59-3A971B79C4F8 Q42686586-C4386A7D-4D63-48E2-8E9B-1F87968F7B5C Q45823744-F6E3323E-4677-4F25-8F51-12C0733C7CF1 Q47914665-00377C14-5504-4E58-91FF-5E13A174F270 Q49793170-19DADA64-8ACF-44F1-9DC1-90268D9EA0F7 Q51374662-028A9973-812D-4425-8D6F-9F11885AEA44 Q53513354-CB24A22A-1C72-4D32-B8DA-C109ECE5F260 Q54464377-6AC805DE-7DEE-4D90-8E61-84A3E431E4C6

P2860

Febuxostat inhibition of endothelial-bound XO: implications for targeting vascular ROS production.

http://www.wikidata.org/entity/Q42127578

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Febuxostat inhibition of endot ...... eting vascular ROS production.

@en

Febuxostat inhibition of endot ...... eting vascular ROS production.

@nl

type

label

Febuxostat inhibition of endot ...... eting vascular ROS production.

@en

Febuxostat inhibition of endot ...... eting vascular ROS production.

@nl

prefLabel

Febuxostat inhibition of endot ...... eting vascular ROS production.

@en

Febuxostat inhibition of endot ...... eting vascular ROS production.

@nl

P1433

Q42127578-07ECE5B8-502E-498F-BAE3-86C91F791B6E

P1476

Q42127578-6327E471-1EDC-4B17-81DF-6E8CD8A15A77

P2093

Q42127578-09B048B0-788A-4DB5-8127-9F88CF4ACDF5

Q42127578-268045F3-3132-4C25-B27C-983ECB4B617A

Q42127578-39577102-126F-4CB3-8706-1EBB40DC1062

Q42127578-434B55F5-2466-41D8-B4D2-73DC8B0CA0DF

Q42127578-5D754D02-C0A3-40EF-BACB-C75448E7C593

Q42127578-A53EF266-5452-41E6-B5F4-FAD868856B9B

Q42127578-AFABD084-034F-4662-97D9-9CE7F1E6DBBB

P2860

Q42127578-0401C2F3-7833-4833-8206-CBEABFE272C7

Q42127578-0BB36309-E337-4615-9586-550648D12788

Q42127578-0F3AB84B-AF18-48D1-9A72-E509700C9A79

Q42127578-2DA35B37-D9DE-404F-B04E-248A1C43429F

Q42127578-49C9821C-4829-45EC-9215-FB10B861E8D1

Q42127578-7997C139-91A3-4313-91E8-E84ABB0F70A2

Q42127578-8A764690-8270-43A4-81CF-C283C4A8FC11

Q42127578-A74035B0-347D-475A-A90D-6E52819752D0

Q42127578-AD655511-6E42-48EF-AF73-AC47B6831272

Q42127578-B725AA52-4C3B-4495-87DA-1E2C3812C5E3

P304

Q42127578-968EA374-AE4A-4A26-9ED8-6CC33509E1C8

P31

Q42127578-EB0B9213-3836-4669-BA1A-7504E8265E89

P356

Q42127578-319C0B92-5DAA-4D4B-84F5-6DF29C70114B

P433

Q42127578-AFE097FE-9F75-4C8E-9130-52C57A16B1F1

P478

Q42127578-24463B67-4143-44A9-9958-23067EFA03FB

P577

Q42127578-AC31D4BF-4552-4D12-BEF7-D44E0EA1C36B

P5875

Q42127578-A91EE06A-53D5-4AF5-AC46-5561C9A158D1

P698

Q42127578-518F93AA-8C5A-4916-9491-6B6B0BE745B2

P921

Q42127578-52C93590-1D8F-43D0-ADFB-E9B4469FA042

P932

Q42127578-0C35C713-6B36-4332-816A-BC6B946DC535

P356

J.FREERADBIOMED.2011.04.004

P1433

Free Radical Biology and Medicine

P1476

Febuxostat inhibition of endot ...... eting vascular ROS production.

@en

P2093

Bruce A Freeman

http://www.w3.org/2001/XMLSchema#string

Eric E Kelley

http://www.w3.org/2001/XMLSchema#string

Guillermo Romero

http://www.w3.org/2001/XMLSchema#string

Margaret M Tarpey

http://www.w3.org/2001/XMLSchema#string

Nicholas J Hundley

http://www.w3.org/2001/XMLSchema#string

Rafael Radi

http://www.w3.org/2001/XMLSchema#string

Umair Z Malik

http://www.w3.org/2001/XMLSchema#string

P2860

Crystal structures of bovine milk xanthine dehydrogenase and xanthine oxidase: structure-based mechanism of conversion

An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition

Allopurinol kinetics

Proteolytic conversion of xanthine dehydrogenase from the NAD-dependent type to the O2-dependent type. Amino acid sequence of rat liver xanthine dehydrogenase and identification of the cleavage sites of the enzyme protein during irreversible convers

Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease.

On the mechanism of inactivation of xanthine oxidase by allopurinol and other pyrazolo[3,4-d]pyrimidines.

Febuxostat compared with allopurinol in patients with hyperuricemia and gout.

Crystal structures of mammalian xanthine oxidoreductase bound with various inhibitors: allopurinol, febuxostat, and FYX-051.

Production of extracellular superoxide by human lymphoblast cell lines: comparison of electron spin resonance techniques and cytochrome C reduction assay

The mechanism of conversion of rat liver xanthine dehydrogenase from an NAD+-dependent form (type D) to an O2-dependent form (type O).

P304

179-184

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.FREERADBIOMED.2011.04.004

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

51

http://www.w3.org/2001/XMLSchema#string

P577

2011-04-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51110165

http://www.w3.org/2001/XMLSchema#string

P698

21554948

http://www.w3.org/2001/XMLSchema#string

P921

P932

3130629

http://www.w3.org/2001/XMLSchema#string